Skip to content
The Policy VaultThe Policy Vault

Sutent — Medica

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes (FLT3 rearrangement)

Initial criteria

  • age ≥ 18 years
  • Patient has eosinophilia
  • Tumor has an FLT3 rearrangement

Approval duration

1 year